| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T192 |
0-30 |
Sentence |
denotes |
Lactoferrin as a Nutraceutical |
| T193 |
31-348 |
Sentence |
denotes |
There is little doubt that oral LF can be of health benefit to the host, and while it is not considered to be absolutely necessary for mammalian life (so it is not a vitamin), it is reasonable to class it as a nutraceutical along with a variety of other molecules such as those mentioned in various papers (180, 181). |
| T194 |
349-494 |
Sentence |
denotes |
As a nutraceutical, the bioavailability of LF would clearly be an important consideration in its use for the prevention or treatment of COVID-19. |
| T195 |
495-660 |
Sentence |
denotes |
Enteric coating of LF capsules has been proposed as a measure to maximize the uptake of LF by the receptors located in the brush-border of the small intestine (182). |
| T196 |
661-921 |
Sentence |
denotes |
Enteric coating allows LF release some distance from LF-degrading pepsin activities in the stomach, allowing it to remain intact, in the form capable of binding small intestinal LF receptors for uptake and eventual transfer into the systemic circulation (182). |
| T197 |
922-1098 |
Sentence |
denotes |
In a rodent study, the “absorption” of enteric-formulated LF was approximately 10-fold higher than that of regular LF introduced into the stomach of experimental animals (128). |
| T198 |
1099-1371 |
Sentence |
denotes |
In view of these investigations, the authors of this paper regard enteric-coated LF as superior to regular LF supplements with respect to bioavailability and potential application for the prevention or therapy for coronaviruses such as the SARS-Cov-2 involved in COVID-19. |
| T199 |
1373-1445 |
Sentence |
denotes |
Nutritional Sources, Availability and Uses for Lactoferrin as Supplement |
| T200 |
1446-1513 |
Sentence |
denotes |
There is considerable LF availability in various forms and sources. |
| T201 |
1514-1630 |
Sentence |
denotes |
Table 3 shows some of the sources and the references to research where it has been used to treat various conditions. |
| T202 |
1631-1740 |
Sentence |
denotes |
Table 3 Lactoferrin sources as supplements, and examples where it has been used to treat various conditions. |
| T203 |
1741-1775 |
Sentence |
denotes |
Lactoferrin sources as supplements |
| T204 |
1776-1796 |
Sentence |
denotes |
Product References |
| T205 |
1797-1941 |
Sentence |
denotes |
Bovine and human milk Morinaga Industries in Japan (183) DoMO Food Ingredients, a subsidiary of Friesland Dairy Foods, in the Netherlands (184) |
| T206 |
1942-2032 |
Sentence |
denotes |
Human recombinant lactoferrin Talactoferrin from Agennix, Inc., Houston, Texas, USA (184) |
| T207 |
2033-2131 |
Sentence |
denotes |
Lactoferrin expression in transgenic rice Ventrus Biosciences, New York City, New York, USA (184) |
| T208 |
2132-2190 |
Sentence |
denotes |
Transgenic cattle expressing human lactoferrin (185, 186) |
| T209 |
2191-2262 |
Sentence |
denotes |
Transgenic maize Meristem therapeutics, Clermont-Ferrand, France (184) |
| T210 |
2263-2323 |
Sentence |
denotes |
Lactoferrin supplementation in treatment of various diseases |
| T211 |
2324-2414 |
Sentence |
denotes |
Might be useful in treating sepsis or necrotizing enterocolitis in preterm neonates (184) |
| T212 |
2415-2448 |
Sentence |
denotes |
Support for vaginal health (187) |
| T213 |
2449-2646 |
Sentence |
denotes |
LF may play a protective role in host defense against SARS-CoV infection through binding to HSPGs and blocking the preliminary interaction between SARS-CoV and host cells (cell culture study) (99) |
| T214 |
2647-2820 |
Sentence |
denotes |
LF is a modulator of innate immune responses in the urinary tract and has potential application in novel therapeutic design for urinary tract infection (animal study) (188) |
| T215 |
2821-2903 |
Sentence |
denotes |
Possible therapy against Candida albicans in the oral cavity (a hypothesis) (189) |
| T216 |
2904-2972 |
Sentence |
denotes |
Protection against Chlamydia trachomatis (cell culture study) (190) |
| T217 |
2973-3040 |
Sentence |
denotes |
Treatment of taste and smell abnormalities after chemotherapy (52) |
| T218 |
3041-3114 |
Sentence |
denotes |
LF supplements and food with high levels of LF for oral health (99, 191) |
| T219 |
3115-3211 |
Sentence |
denotes |
LF treatment of black stain associated with of iron metabolism disorders with lactoferrin (192) |
| T220 |
3212-3378 |
Sentence |
denotes |
Aerosolized bovine LF counteracts infection, inflammation and iron dysbalance in a cystic fibrosis mouse model of Pseudomonas aeruginosa chronic lung infection (193) |
| T221 |
3379-3416 |
Sentence |
denotes |
LF inhalations for lung health (194) |
| T222 |
3417-3452 |
Sentence |
denotes |
LF for optimal skin moisture (195) |
